Described herein are therapeutic approaches with immune modifiers of the Th2 pathway for the treatment of allergic and inflammatory diseases. Aspects of the disclosure relate to methods for decreasing Th2 type cell responses in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an anti Dectin antibody or antigen binding fragment there of operatively linked to a TLR agonist.
